# Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

> **NCT01982955** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 88 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Tepotinib
- **DRUG:** Gefitinib
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01982955
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-23
- **Primary completion:** 2017-12-12
- **Final completion:** 2021-10-14
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982955, "Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01982955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*